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pack and its side effects are among the lowest. Alterna-
tively, olanzapine was the most effective agent, even
though it was associated with the most weight gain and
other metabolic side effects. Others might consider
that perphenazine, which was in the middle range in
effectiveness and side effects but cost much less than
the others, is the best in terms of cost effectiveness.
Drug companies might be expected to selectively
focus on the small marginal benefits of drugs they
manufacture and sell. But pharmaceutical giants are
not the only parties with financial conflicts of interest.
Government agencies and insurance companies, with
vested interests in paying as little as possible for care,
might choose to focus on the lack of significant differ-
ence between older and newer agents, since the older
ones have a clear cost advantage, and recommend the
older agents as the best initial choice for patients.
Many questions remain.9 In the CATIE trial the
dosing of all agents except olanzapine was set at or
below that recommended by the Food and Drug
Administration, while olanzapine could be given at
50% above the recommended dose. Could the (slight)
advantage of olanzapine be a function of the higher
dose? The study was not long enough to adequately
assess the true health consequences of the metabolic
changes, even though these adverse effects, as opposed
to more immediate neurological problems, might be
life shortening in the long run. Clozapine, which, yet
again, turned out to be the best choice for those who
did not respond to another agent,10 also produced
troubling metabolic effects. Thus, choosing among the
available antipsychotic agents involves difficult trade-
offs. Truly novel agents are still needed.
What are clinicians to make of all this, in terms of
selecting an antipsychotic drug for their patients? Patients
themselves (and their care givers) need to be involved in
the choice and informed about data thatmight help them
with the decision. Such information should include the
fact that efficacy differences between older and newer
drugs (with the exception of clozapine) are small, if they
exist at all. Patients and care givers should also be aware
of the trade-offs between fewer neurological side effects
(including akathisia, parkinsonism, or tardive dyskinesia)
andmore adverse metabolic effects (such as weight gain,
hyperlipidaemia, and hyperglycaemia).
For patients who do not respond well to one anti-
psychotic drug the evidence is consistently in favour of
clozapine as the agent most likely to be effective. Yet the
rates of clozapine prescribing appear to be far below
what would be expected if this was being recommended
for all patients who do not respond to treatment. Not
only clinicians but patients and families may need to be
better educated about clozapine, and treatment guide-
lines need to be revised to reinforce this.
Cost may be a critical barrier to accessing medica-
tion, particularly for long term treatment. Clinicians
and patients for whom cost is a key concern should be
relieved to know that the cheaper older antipsychotics
have not become obsolete.
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Should UK allergy services focus on primary care?
The time is ripe to rise to this challenge
The marked increase in the prevalence ofallergic disease over the past few decades hasleft the NHS ill prepared. In response to the
Health Select Committee’s damning report in 2004 on
allergy services,1 the Department of Health and the
Scottish Executive are currently reviewing all aspects of
provision of allergy care. Their separate reports will be
published shortly. A key question is whether it would
be more effective for the NHS to emulate the model
used in other parts of Europe and North America and
invest in expanding specialist services for allergy
or—more controversially—to concentrate efforts on
developing primary care services. This choice will have
substantial and lasting implications for people with
allergies in the United Kingdom and will probably
affect the thinking of policy makers in other parts of
the world who are grappling with similar rapid
increases in the prevalence of allergic disease.
Around one in three of the UK population have
allergic symptoms at some point in their lives.2
Localised or organ specific allergic disorders such as
atopic eczema, allergic rhinitis, and asthma are
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common, and small but increasing numbers of patients
are now also experiencing more acute systemic allergic
disorders such as anaphylaxis.3 Multiple allergies are
common, affecting an estimated 10% of children and
young people ( < 45 years) and 5% of older people and
are particularly problematic to manage, both for
patients and healthcare providers.2 4 5
Most patients with allergic problems manage their
own conditions and seek help from their primary care
teams when necessary. Some also need support from
general paediatricians and specialists such as chest
physicians and, in some regions, from clinical
immunologists and allergists. However, this model of
care has serious drawbacks.1
Most doctors trained in the United Kingdom have
had few opportunities for undergraduate or post-
graduate training in the diagnosis, assessment, and
management of patients with allergic problems. Also,
accurate diagnosis is hampered by the difficulty in
obtaining, financing, and interpreting simple diagnos-
tic tests, such as skin prick and specific IgE testing. Fur-
thermore, in more complex cases needing specialist
advice the lack of allergy specialists means that primary
care teams typically have little choice but to refer to
local specialists with limited expertise in managing
multisystem disease.
Patients often have to see more than one
specialist—for example an ear, nose, and throat
surgeon for allergic rhinitis; a gastroenterologist for
food allergy; and a respiratory physician for asthma.4
Currently, only eight specialist allergy centres in the
United Kingdom provide a comprehensive package of
care led by a consultant allergist, and all of them are in
England.6
The national campaign to improve the provision of
allergy services has focused so far on lobbying for
more specialist training posts, with little success.2 7
Given the very large numbers of patients with multiple
allergies, the demonstrable failure of allergen avoid-
ance measures in improving clinical outcomes for
patients with eczema, allergic rhinitis, and asthma,2 8 9
and the costs of establishing consultant led specialist
centres, we believe it would be more pragmatic to
improve service provision in primary care. The report
by the House of Commons Health Select Committee
and the Department of Health’s response to it10 agreed
that primary care organisations should focus on devel-
oping and implementing local service models for
managing allergy.2
Wider training and better access to allergy testing
throughout general practice would be welcome, but an
intermediate level of specialism could be provided by
regional practitioners with specialist interests in
allergy, who could also act as catalysts for a wider
primary care based allergy service. A regional
practitioner (a general practitioner or nurse consult-
ant) with a specialist interest in allergy would organise
an allergy clinic to serve a whole primary care trust,
taking referrals from local practitioners.
Unpublished data from Education for Health—a
training organisation for primary care staff—show that
approximately 800 primary care staff have had
diploma level training in allergy that would prepare
them for this role.11 12 Furthermore, this model is
already running in at least three parts of the United
Kingdom, with support from and the ability to refer
patients to one or more specialist centres. No prospec-
tive evaluations from these units have been published
yet, however.
Advocating primary care led allergy services in the
current financial climate in the NHS carries the risk
that nothing will happen. Improving standards of care
will depend on having sufficient resources for better
postgraduate training, better allergy testing, and better
evidence on which outcome measures should be
incorporated into future incarnations of the perform-
ance criteria which general practitioners have to
meet—the UK general medical services quality and
outcomes framework.13
This is not to say that there should be no
investment in secondary and tertiary allergy services.
On the contrary, these services do need more funding
and more equal distribution throughout the United
Kingdom.
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